Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Positive data reported for epitope-based HIV-1 vaccine
September 8th, 2004
Epimmune, Inc., (EPMN) announced the publication of data which showed that an epitope-based HIV-1 vaccine can be designed to induce cytotoxic T lymphocytes (CTL) capable of recognizing viruses from different parts of the world. Worldwide, HIV-1 is characterized by sequence variation caused by mutations or viral recombination events within gene products. This variation has contributed to the evolution of numerous individual virus isolates that are currently categorized into subtypes based on the degree of similarity. The variation between subtypes can be quite extensive but high levels of variation are also seen when comparing individual viral isolates from the same...
Source: Vaccine Weekly (2004-09-08)
|
